All In Biotech

Drug Trial Radar · NCT05735080

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer

Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Mar 28, 2023

Primary completion

Jul 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Incyclix BioIndustry
Sponsor type
Industry
First posted
Feb 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 in patients with recurrent advanced/metastatic cancer, including hormone receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) regimen, and CCNE1-amplified solid tumors who progressed on standard of care treatment. The study will be conducted in 3 parts: Part A (INX-315 monotherapy dose escalation and combination therapy with fulvestrant), Part B (ovarian cancer INX-315 monotherapy dose expansion), and Part C (INX-315 combination therapy with abemaciclib \[a CDK4/6i\] and fulvestrant \[a SERD\] in advanced/metastatic breast cancer; dose escalation and expansion).

Conditions

  • Breast Cancer
  • Breast Cancer Metastatic
  • Hormone Receptor Positive Tumor
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
  • Ovarian Cancer
  • CCNE1 Amplification
  • Solid Tumor
  • Advanced Cancer
  • Metastatic Cancer

Interventions

  • INX-315Drug

    Oral administration

  • FulvestrantDrug

    Fulvestrant will be combined with INX-315

  • AbemaciclibDrug

    Abemaciclib will be combined with INX-315

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A and B: Evaluate the incidents of treatment emergent adverse events and laboratory abnormalities in INX-315 monotherapy and in combination with fulvestrantTime frame: Up to 12 months
  2. Part A: Evaluate the occurrence of dose-limiting toxicities (DLTs) during Cycle 1Time frame: 28 days
  3. Part A: Recommend at least two doses of INX-315 to be evaluated in the expansion phaseTime frame: Up to 12 months
  4. Part B: Overall response rate (ORR)Time frame: Up to 36 months
  5. Part B: Selection of Recommended Phase 2 Dose (RP2D)Time frame: Up to 36 months
  6. Part C Evaluate the incidents of treatment emergent adverse events and laboratory abnormalities for patients in combination treatment (INX_315+abemaciclib+fulvestrant)Time frame: Up to 12 months
  7. Part C - Evaluate the antitumor activity of INX-315 in combination with abemaciclib and fulvestrantTime frame: Up to 12 months

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • Florida Cancer Specialists

    Orlando, Florida · Recruiting

  • Emory Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia · Recruiting

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York · Recruiting

  • Levine Cancer Institute (LCI)- Atrium Health

    Charlotte, North Carolina · Recruiting

  • Duke Cancer Center/ DUMC

    Durham, North Carolina · Recruiting

  • Gabrail Cancer Research Center

    Canton, Ohio · Recruiting

  • Next Oncology

    Dallas, Texas · Recruiting

  • UTSW Medical Center

    Dallas, Texas · Recruiting

  • Oncology Consultants

    Houston, Texas · Not yet recruiting

  • Next Oncology

    Houston, Texas · Recruiting

  • Northwest Medical Specialties, PLLC

    Tacoma, Washington · Recruiting

  • Mater Hospital

    South Brisbane, Australia · Recruiting

  • Peninsula and South Eastern Haematology & Oncology Group

    Frankston, Victoria, Australia · Recruiting

  • Peter MacCallum Cancer Center

    Parkville, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.